Nesiritide is the recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide hormone. It is produced by the ventricular myocardium in response to volume expansion and pressure overload, making it a key cardiac biomarker for heart failure. The peptide was discovered as part of the natriuretic peptide system, which includes atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Its significance lies in its potent vasodilatory, natriuretic (sodium-excreting), and diuretic properties, which counterbalance the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system activation in heart failure.
Nesiritide was developed as a therapeutic agent for acute decompensated heart failure (ADHF) based on the physiological role of endogenous BNP. It received FDA approval in 2001 for the intravenous treatment of patients with ADHF who have dyspnea at rest or with minimal activity. While its clinical use has evolved due to safety debates, it remains a critical tool in cardiovascular research for understanding natriuretic peptide physiology, receptor signaling, and therapeutic modulation in cardiorenal syndromes.
Quick Facts
| Also Known As | B-type natriuretic peptide, BNP, Recombinant human B-type natriuretic peptide, rhBNP |
|---|---|
| Sequence | Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His |
| Molecular Formula | C143H244N50O42S4 |
| Molecular Weight | 3464.0 Da |
| PubChem CID | 71308561 |
Research Parameters
| Half-Life | Approximately 18 minutes in humans |
|---|---|
| Stability | Lyophilized powder is stable when stored as directed. After reconstitution as directed for IV infusion, solutions are typically used immediately but may be stored at 2-8°C for up to 24 hours. Specific stability data for research-grade lyophilized material is vendor-dependent. |
| Solubility | For clinical use, reconstituted per manufacturer instructions with prescribed diluent (typically 5% Dextrose Injection, USP). For laboratory research, it may be reconstituted in sterile water or appropriate buffer (e.g., phosphate-buffered saline) depending on experimental protocol. |
| Vial Size | 1.5 mg |
| Storage (Lyophilized) | Store lyophilized powder at -20°C, protect from light and moisture. |
| Storage (Reconstituted) | After reconstitution for research, store at 2-8°C for short-term use (typically ≤24 hours). For long-term storage, aliquot and store at ≤-20°C or -80°C. Avoid repeated freeze-thaw cycles. |
| Typical Research Dose | In clinical research: 2 mcg/kg IV bolus followed by 0.01 mcg/kg/min continuous infusion. Laboratory research doses vary widely based on model (in vitro nM concentrations, in vivo animal models at mcg/kg doses). |
| Cycle Parameters | In clinical research for acute heart failure: Continuous intravenous infusion typically for 24 to 48 hours. No standard "cycle" as used in chronic peptide therapy; administration is acute and symptom-driven. Laboratory animal study protocols vary from single bolus injections to continuous infusions over several days. |
| Amino Acid Count | 32 |
Mechanism of Action
Nesiritide exerts its effects primarily by binding to and activating the particulate guanylyl cyclase-linked natriuretic peptide receptor A (NPR-A), which is highly expressed in vascular smooth muscle cells, endothelial cells, kidneys, and adrenal glands. Activation of NPR-A leads to increased intracellular cyclic guanosine monophosphate (cGMP), which serves as the principal second messenger mediating the peptide's biological actions.
Vasodilation: Increased cGMP in vascular smooth muscle cells leads to activation of protein kinase G (PKG), resulting in phosphorylation of proteins that reduce intracellular calcium concentrations. This causes smooth muscle relaxation and arterial and venous dilation, reducing preload and afterload on the heart.
Natriuresis and Diuresis: In the kidneys, cGMP-mediated signaling in the glomeruli and inner medullary collecting ducts increases glomerular filtration rate (GFR) and inhibits sodium reabsorption. It also suppresses renin secretion and aldosterone synthesis, further promoting sodium and water excretion.
Inhibition of RAAS and Sympathetic Activity: Nesiritide inhibits the release of renin from the juxtaglomerular cells and aldosterone from the adrenal cortex. It also modulates sympathetic nervous system outflow, contributing to reduced systemic vascular resistance and myocardial oxygen demand.
Lusitropic Effects: By reducing cardiac filling pressures and wall stress, nesiritide may improve ventricular relaxation (lusitropy), although this is a secondary effect of its primary unloading actions.
Research Applications
Cardiovascular Research: Nesiritide is extensively studied in models of heart failure, hypertension, and myocardial remodeling. Research focuses on its hemodynamic effects, impact on neurohormonal activation, and potential role in mitigating ventricular hypertrophy and fibrosis. Studies investigate its use in acute decompensation, as well as in chronic settings to understand long-term modulation of natriuretic peptide pathways.
Renal Research: Investigations explore the peptide's complex effects on renal function, particularly in cardiorenal syndrome. Research aims to delineate the mechanisms behind its natriuretic and diuretic actions versus potential reductions in glomerular filtration rate observed in some clinical scenarios, studying receptor distribution and cGMP signaling in different nephron segments.
Biomarker and Diagnostic Research: As the recombinant form of BNP, nesiritide is used in assay development and validation for measuring endogenous BNP levels. Research utilizes it to calibrate diagnostic tests and to study the clearance and metabolism of BNP, including the role of neutral endopeptidase (NEP) and the NPR-C clearance receptor.
Pulmonary Research: Studies examine its effects on pulmonary vasculature and right heart function. Research investigates its potential to reduce pulmonary artery pressure and pulmonary capillary wedge pressure, making it a tool for studying pulmonary hypertension associated with left heart disease.
Dosage Information
This information is derived from historical clinical research and is presented for research and educational purposes only. Nesiritide is not for human use outside of approved clinical settings.
In clinical trials for acute decompensated heart failure, nesiritide was administered as an intravenous (IV) bolus followed by a continuous IV infusion. The typical research dose range was a 2 mcg/kg IV bolus followed by a continuous infusion of 0.01 mcg/kg/min. Dose adjustments were made based on hemodynamic response. The route of administration is exclusively intravenous. The frequency is continuous infusion. Duration of infusion in studies typically ranged from 24 to 48 hours, though some protocols extended up to 96 hours.
References
Colucci, W.S., Elkayam, U., Horton, D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. New England Journal of Medicine, 2000, 343(4), 246-253.
Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA, 2002, 287(12), 1531-1540.
Mills, R.M., LeJemtel, T.H., Horton, D.P., et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Journal of the American College of Cardiology, 1999, 34(1), 155-162.
Sackner-Bernstein, J.D., Skopicki, H.A., Aaronson, K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation, 2005, 111(12), 1487-1491.
Chen, H.H., Sundt, T.M., Cook, D.J., Heublein, D.M., Burnett, J.C. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation, 2007, 116(11_suppl), I-134-I-138.
O'Connor, C.M., Starling, R.C., Hernandez, A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. New England Journal of Medicine, 2011, 365(1), 32-43.